Top Swedish (OMX) Growth Stocks

Top Swedish (OMX) Growth Stocks

UPDATED Aug 13, 2022

What are the best Swedish (OMX) Growth Stocks?

According to our Simply Wall St analysis these are the best Swedish growth companies. We look for companies with high forecasted growth and healthy balance sheets that can deliver sustained growth over the long term.

Our criteria to find Top Growth Companies

Growth

  • Companies with sustained revenue growth that outperforms the market are attractive to investors. These companies are most likely to appreciate in share price over time.

What do we look for?

  • Is the company forecast to have high earnings growth.

Healthy Balance Sheet

  • A healthy balance sheet is essential to drive growth opportunities and sustain the business.
  • Repayments on debt take precedence over other initiatives to improve shareholder returns, so investors want to make sure the company is comfortably positioned to cover its debts.

What do we look for?

  • Does the company have a manageable level of debt.
  • Is the company able to cover its interest repayments.

33 companies meet this criteria in the Swedish market

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: CALTX is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 98.3% below our estimate of its fair value

  • Earnings are forecast to grow 60.2% per year

Risks

  • Shareholders have been diluted in the past year

View all Risks and Rewards

Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: CAMX is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 79.6% below our estimate of its fair value

  • Earnings are forecast to grow 52.32% per year

  • Earnings have grown 12.6% per year over the past 5 years

Risks

No risks detected for CAMX from our risks checks.

View all Risks and Rewards

Tempest Security AB (publ) provides security and protection solutions worldwide.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: TSEC is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 91.5% below our estimate of its fair value

  • Earnings are forecast to grow 77.71% per year

Risks

  • Does not have a meaningful market cap (SEK209M)

  • Shareholders have been diluted in the past year

View all Risks and Rewards

TF Bank AB (publ) provides consumer banking services and e-commerce solutions through a proprietary IT platform.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: TFBANK's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 56% below our estimate of its fair value

  • Earnings are forecast to grow 22.09% per year

  • Earnings grew by 29.4% over the past year

Risks

No risks detected for TFBANK from our risks checks.

View all Risks and Rewards

Sleep Cycle AB (publ) provides sleep tracking applications in Sweden.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: SLEEP's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 54.2% below our estimate of its fair value

  • Earnings are forecast to grow 31.49% per year

  • Earnings grew by 191.7% over the past year

Risks

  • Does not have a meaningful market cap (SEK818M)

View all Risks and Rewards

Bonesupport Holding AB (publ), an orthobiologics company, develops and commercializes injectable bioceramic bone graft substitutes for the treatment of bone voids in Europe, North America, and internationally.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: BONEX is expected to become profitable in the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 53.1% below our estimate of its fair value

  • Earnings are forecast to grow 120.16% per year

  • Earnings have grown 11.5% per year over the past 5 years

Risks

  • Highly volatile share price over the past 3 months

View all Risks and Rewards

Genovis AB (publ.) designs, develops, and sells tools for development of drugs for customers in the pharmaceutical and medical device industries.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: GENO's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 54.4% below our estimate of its fair value

  • Earnings are forecast to grow 60.63% per year

  • Earnings grew by 208.4% over the past year

Risks

No risks detected for GENO from our risks checks.

View all Risks and Rewards

Truecaller AB (publ), through its subsidiary, True Software Scandinavia AB, operates a communication platform for verifying contacts and blocking unwanted calls and messages worldwide.

Growth Criteria

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings: TRUE B's earnings are expected to grow significantly over the next 3 years.

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE

See Full Stock Report

Rewards

  • Trading at 36.3% below our estimate of its fair value

  • Earnings are forecast to grow 32.21% per year

  • Earnings grew by 222.8% over the past year

Risks

  • Highly volatile share price over the past 3 months

View all Risks and Rewards
Page 1 of 5